PTC Therapeutics, Inc.
PTCT
주식 순위
#3334
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
주가
$62.83
시가총액
$5.24B
변동 (1일)
2.11%
변동 (1년)
-8.09%
국가
US
거래 PTC Therapeutics, Inc. (PTCT)
카테고리
Healthcare
PTC Therapeutics, Inc. (PTCT)의 매출
Jun 2026 기준 매출 TTM: $1.01B
PTC Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $1.01B입니다. 2023년에 회사는 $937.82M의 수익을 올렸으며 이는 2022년의 $698.80M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
PTC Therapeutics, Inc.의 수익 기록 (2011 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.01B | 25.03% |
| 2024 | $806.78M | -13.97% |
| 2023 | $937.82M | 34.20% |
| 2022 | $698.80M | 29.75% |
| 2021 | $538.59M | 41.45% |
| 2020 | $380.77M | 24.04% |
| 2019 | $306.98M | 15.96% |
| 2018 | $264.73M | 36.19% |
| 2017 | $194.39M | 135.04% |
| 2016 | $82.71M | 124.95% |
| 2015 | $36.77M | 60.11% |
| 2014 | $22.96M | -26.70% |
| 2013 | $31.33M | 8.85% |
| 2012 | $28.78M | -70.92% |
| 2011 | $98.96M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 1,151.47% |
US
|
|
| $2.23B | 120.87% |
US
|
|
| $15.74B | 1,460.77% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 496.90% |
NL
|
